AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7% - Here's What Happened

Key Points

• AbCellera shares rose 8.7% to about $10.15 after positive Phase 2 results for ABCL635, which significantly reduced the frequency and severity of menopausal vasomotor symptoms and boosted confidence in the company’s pipeline.
• Investor enthusiasm was reinforced by unusually strong call-option activity, with 16,666 contracts traded—about 151% above average—though this signals speculation rather than a guaranteed further rise.
• Analyst views remain mixed but lean positive: the stock carries a “Moderate Buy” consensus and a $9.40 average price target, despite the company recently missing quarterly revenue and EPS estimates and continuing to report losses.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) traded up 8.7% on Tuesday . The company traded as high as $9.96 and last traded at $10.1520. Approximately 4,091,649 shares changed hands during trading, a decline of 32% from the average daily volume of 5,976,931 shares. The stock had previously closed at $9.34.

AbCellera Biologics News Summary

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results: ABCL635 met its primary efficacy endpoints, significantly reducing the frequency and severity of vasomotor symptoms in the Phase 1/2 trial. The results were described as a potential “new efficacy benchmark,” strengthening investor confidence in AbCellera’s pipeline. AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results
• Positive Sentiment: Large stock-market reaction: Reports said the clinical results sent ABCL shares sharply higher in premarket trading, reflecting optimism that ABCL635 could address a substantial menopause-treatment market without relying on hormone therapy. AbCellera menopause drug cuts hot flashes in mid-stage trial
• Positive Sentiment: Unusually strong call-option demand: Investors purchased 16,666 call options, approximately 151% above the typical daily volume of 6,636 contracts. The activity signals increased near-term bullish speculation, although options positioning does not guarantee further gains. Investors Buy Large Volume of AbCellera Biologics Call Options

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ABCL shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Friday, July 17th. Wall Street Zen lowered shares of AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Benchmark upgraded AbCellera Biologics from a "hold" rating to a "buy" rating and set a $11.00 price objective for the company in a research note on Tuesday, July 7th. Stifel Nicolaus boosted their price objective on AbCellera Biologics from $8.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald raised their target price on AbCellera Biologics from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, AbCellera Biologics has a consensus rating of "Moderate Buy" and an average target price of $9.40.

AbCellera Biologics Trading Up 5.5%

The company has a market cap of $3.02 billion, a price-to-earnings ratio of -18.23 and a beta of 1.20. The business has a fifty day moving average of $6.28 and a two-hundred day moving average of $4.73.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The business had revenue of $4.05 million during the quarter, compared to analyst estimates of $7.85 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. On average, research analysts forecast that AbCellera Biologics Inc. will post -0.67 EPS for the current fiscal year.

Institutional Trading of AbCellera Biologics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AssuredPartners Investment Advisors LLC purchased a new position in AbCellera Biologics in the 4th quarter valued at about $34,000. Voleon Capital Management LP acquired a new position in shares of AbCellera Biologics during the third quarter valued at approximately $56,000. Engineers Gate Manager LP purchased a new position in shares of AbCellera Biologics in the fourth quarter valued at approximately $38,000. Allworth Financial LP boosted its stake in shares of AbCellera Biologics by 857.0% in the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company's stock worth $39,000 after acquiring an additional 10,096 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of AbCellera Biologics in the first quarter worth approximately $46,000. Hedge funds and other institutional investors own 61.42% of the company's stock.

About AbCellera Biologics

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source